|Dr. Terrence W. Norchi||Chairman, Pres, CEO, Sec. & Director||552.5k||N/A||1965|
|Mr. Richard E. Davis||CFO & Treasurer||406.25k||N/A||1958|
|Dr. Avtar S. Dhillon||Bus. Advisor||152k||N/A||1961|
|Mr. Rutledge Ellis-Behnke||Co-Founder & Scientific Advisor||N/A||N/A||N/A|
|Dr. Steven A. Kates Ph.D.||VP of Technology||N/A||N/A||N/A|
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
Arch Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.